Subscribe
Alert
Claudia J. Frehe, Ph.D.
Associate
Suite 900
Washington, D.C., 20001
*Admitted and practicing before the Patent and Trademark Office. Not admitted to the District of Columbia Bar, but practicing under the supervision of a D.C. Bar Member pursuant to D.C. Bar R. 49(c)(8).
Claudia focuses her practice on the development and execution of global intellectual property strategies for clients in the biotechnology and pharmaceutical sectors. She advises on all aspects of patent portfolio development and management, including freedom-to-operate analyses, patent validity and non-infringement, IP due diligence, and defensive and counteroffensive patent strategies. Claudia also regularly counsels emerging biotech...
Claudia focuses her practice on the development and execution of global intellectual property strategies for clients in the biotechnology and pharmaceutical sectors. She advises on all aspects of patent portfolio development and management, including freedom-to-operate analyses, patent validity and non-infringement, IP due diligence, and defensive and counteroffensive patent strategies. Claudia also regularly counsels emerging biotech companies on intellectual property strategies that support fundraising, collaborations, and successful product commercialization.
Claudia’s experience spans a broad range of technologies, including CAR-T cell therapy, gene therapy, antibody therapeutics, immuno-oncology, solid organ and stem cell transplantation, CRISPR, oral vaccines, and biomanufacturing. She also represents clients in the medtech and foodtech industries.
Claudia brings a strong scientific foundation to her legal practice. She earned her Ph.D. in translational biology and molecular medicine from Baylor College of Medicine, where her research focused on CAR-T immunotherapy. She subsequently completed a postdoctoral fellowship at the National Cancer Institute in the Experimental Transplantation and Immunology Branch. Prior to her legal career, Claudia worked as a certified molecular biologist, conducting histocompatibility testing in support of organ and stem cell transplantation at Houston Methodist Hospital.
companies on intellectual property strategies that support fundraising, collaborations, and successful product commercialization.
Claudia’s experience spans a broad range of technologies, including CAR-T cell therapy, gene therapy, antibody therapeutics, immuno-oncology, solid organ and stem cell transplantation, CRISPR, oral vaccines, and biomanufacturing. She also represents clients in the medtech and foodtech industries.
Claudia brings a strong scientific foundation to her legal practice. She earned her Ph.D. in translational biology and molecular medicine from Baylor College of Medicine, where her research focused on CAR-T immunotherapy. She subsequently completed a postdoctoral fellowship at the National Cancer Institute in the Experimental Transplantation and Immunology Branch. Prior to her legal career, Claudia worked as a certified molecular biologist, conducting histocompatibility testing in support of organ and stem cell transplantation at Houston Methodist Hospital.
Experience
Previous Professional Experience
- Senior Patent Agent, Global law firm (2021–2025)
- Patent Agent and Scientific Advisor, Global law firm (2015–2021)
- Postdoctoral Fellow for Dr. James Kochenderfer, National Cancer Institute (2014–2015)
Publications
- Co-Author, “Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7." Molecular Therapy 29.2 (2021): 702-717.
- Co-Author, “Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains." Human Gene Therapy 32.13-14 (2021): 730-743.
- Co-Author, “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.” Mol Ther. 2017 Nov 1;25(11):2452-2465.
- Co-Author, “Chimeric antigen receptors for cancer immunotherapy." Tumor Immunology: Methods and Protocols (2016): 75-8.
- Co-Author, “Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.” Expert Opinion on Therapeutic Targets, 2016, 19(10), 1339–1350.
- Co-Author, “The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor.” Molecular Therapy, 2016, 24, S32-S33.
- Co-Author, “Chimeric antigen receptor-redirected T cells return to the bench.” Seminars in Immunology, Volume 28, Issue 1, 2016, 3-9.
- Co-Author, “T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo.” Clin Cancer Res (2014) 20 (4): 962–971.
Education
- University of New Hampshire, Franklin Pierce School of Law, JD, Certificate in Intellectual Property and Technology Law (2025)
- Baylor College of Medicine, PhD, Translational Biology and Molecular Medicine (2014)
- The University of Texas, MD Anderson Cancer Center, MB, Molecular Genetics (2008)
- The University of Texas at Austin, BA/BS (2006)
Admissions
- U.S. Patent & Trademark Office
Practice Areas
Previous Professional Experience
- Senior Patent Agent, Global law firm (2021–2025)
- Patent Agent and Scientific Advisor, Global law firm (2015–2021)
- Postdoctoral Fellow for Dr. James Kochenderfer, National Cancer Institute (2014–2015)
Publications
- Co-Author, “Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7." Molecular Therapy 29.2 (2021): 702-717.
- Co-Author, “Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains." Human Gene Therapy 32.13-14 (2021): 730-743.
- Co-Author, “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.” Mol Ther. 2017 Nov 1;25(11):2452-2465.
- Co-Author, “Chimeric antigen receptors for cancer immunotherapy." Tumor Immunology: Methods and Protocols (2016): 75-8.
- Co-Author, “Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.” Expert Opinion on Therapeutic Targets, 2016, 19(10), 1339–1350.
- Co-Author, “The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor.” Molecular Therapy, 2016, 24, S32-S33.
- Co-Author, “Chimeric antigen receptor-redirected T cells return to the bench.” Seminars in Immunology, Volume 28, Issue 1, 2016, 3-9.
- Co-Author, “T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo.” Clin Cancer Res (2014) 20 (4): 962–971.
Professional Activities
- Hispanic National Bar Association
Claudia focuses her practice on the development and execution of global intellectual property strategies for clients in the biotechnology and pharmaceutical sectors. She advises on all aspects of patent portfolio development and management, including freedom-to-operate analyses, patent validity and non-infringement, IP due diligence, and defensive and counteroffensive patent strategies. Claudia also regularly counsels emerging biotech... companies on intellectual property strategies that support fundraising, collaborations, and successful product commercialization.
Claudia’s experience spans a broad range of technologies, including CAR-T cell therapy, gene therapy, antibody therapeutics, immuno-oncology, solid organ and stem cell transplantation, CRISPR, oral vaccines, and biomanufacturing. She also represents clients in the medtech and foodtech industries.
Claudia brings a strong scientific foundation to her legal practice. She earned her Ph.D. in translational biology and molecular medicine from Baylor College of Medicine, where her research focused on CAR-T immunotherapy. She subsequently completed a postdoctoral fellowship at the National Cancer Institute in the Experimental Transplantation and Immunology Branch. Prior to her legal career, Claudia worked as a certified molecular biologist, conducting histocompatibility testing in support of organ and stem cell transplantation at Houston Methodist Hospital.
Experience
The following is a selected sampling of matters and is provided for informational purposes only. Past success does not indicate the likelihood of success in any future matter.Previous Professional Experience
- Senior Patent Agent, Global law firm (2021–2025)
- Patent Agent and Scientific Advisor, Global law firm (2015–2021)
- Postdoctoral Fellow for Dr. James Kochenderfer, National Cancer Institute (2014–2015)
Publications
- Co-Author, “Development of CAR T cells expressing a suicide gene plus a chimeric antigen receptor targeting signaling lymphocytic-activation molecule F7." Molecular Therapy 29.2 (2021): 702-717.
- Co-Author, “Design and assessment of novel anti-CD30 chimeric antigen receptors with human antigen-recognition domains." Human Gene Therapy 32.13-14 (2021): 730-743.
- Co-Author, “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.” Mol Ther. 2017 Nov 1;25(11):2452-2465.
- Co-Author, “Chimeric antigen receptors for cancer immunotherapy." Tumor Immunology: Methods and Protocols (2016): 75-8.
- Co-Author, “Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.” Expert Opinion on Therapeutic Targets, 2016, 19(10), 1339–1350.
- Co-Author, “The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor.” Molecular Therapy, 2016, 24, S32-S33.
- Co-Author, “Chimeric antigen receptor-redirected T cells return to the bench.” Seminars in Immunology, Volume 28, Issue 1, 2016, 3-9.
- Co-Author, “T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo.” Clin Cancer Res (2014) 20 (4): 962–971.
Education
- University of New Hampshire, Franklin Pierce School of Law, JD, Certificate in Intellectual Property and Technology Law (2025)
- Baylor College of Medicine, PhD, Translational Biology and Molecular Medicine (2014)
- The University of Texas, MD Anderson Cancer Center, MB, Molecular Genetics (2008)
- The University of Texas at Austin, BA/BS (2006)
Admissions
- U.S. Patent & Trademark Office
Practice Areas
- Intellectual Property
- Patent Counseling & Prosecution
- Life Sciences - IP
- FDA Regulatory Compliance & Litigation
Industries
- Hispanic National Bar Association
Highlights from the Firm’s Insights
